Is BridgeBio Pharma, Inc. (BBIO) a Buy, Sell, or Hold?
NASDAQ : BBIO
BridgeBio Pharma, Inc. — Analyst Ratings
$80.09 USD
-$2.05 (-2.5%)
- Volume
- 2.12M
- Average Volume
- 3.44M
- Market Capitalization
- $15.69B
- P/E Ratio
- -21.36
- Dividend Yield
- 0.00%
- Price Target
- $100.00
- Year High
- $93.42
- Year Low
- $42.09
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.44
Analyst Consensus Summary
Consensus Rating
Sell
26 Analysts
Rating Score
2/5
Recommendation Strength
Upside/Downside
-19.9%
vs Current Price
Price Target
$100.00
Average TargetPrice Target Range
Lowest Target
$83.00
-3.5% DOWNSIDE
Average Target
$100.00
Median Estimate
Highest Target
$130.00
-38.4% DOWNSIDEAnalyst Breakdown
Overall Consensus: Buy | Total Analysts: 26
| Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|
| 0 | 23 | 3 | 0 | 0 |
Analyst Ratings (Detailed)
| Analyst Company | Analyst Name | Price Target | Price When Posted | Date | Upside/Downside |
|---|---|---|---|---|---|
| Mizuho Securities | Salim Syed | $96 | $68 | 2026-06-16 06:40 AM | 41.2% |
| Truist Financial | Danielle Brill | $102 | $70.08 | 2026-04-29 08:46 AM | 45.5% |
| RBC Capital | Luca Issi | $100 | $74.14 | 2026-04-08 04:20 PM | 34.9% |
| Leerink Partners | Mani Foroohar | $98 | $68.77 | 2026-03-12 09:24 AM | 42.5% |